
-
Karyopharm Therapeutics NasdaqGS:KPTI Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Location: 85 Wells Avenue, Newton, MA, 02459-3298, United States | Website: https://www.karyopharm.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
236.2M
Cash
69.94M
Avg Qtr Burn
-30.69M
Short % of Float
25.11%
Insider Ownership
6.39%
Institutional Own.
42.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XPOVIO (Selinexor) (XPO1 inhibitor) Details Multiple myeloma, Diffuse large B cell lymphoma, Cancer | Approved Quarterly sales | |
XPOVIO (Selinexor) (XPO1 inhibitor) Details Cancer, Endometrial cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib Details Myelofibrosis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Phase 3 Data readout | ||
XPOVIO (Selinexor) Details Myelofibrosis, Primary immune thrombocytopenia | Phase 2 Data readout | |
XPOVIO (Selinexor) (XPO1 inhibitor) Details Myelofibrosis | Phase 2 Data readout | |
Eltanexor Details Myelodysplastic syndrome, Blood cancer | Phase 2 Update | |
XPOVIO (Selinexor) (XPO1 inhibitor) + mezigdomide Details Multiple myeloma | Phase 2 Update | |
KPT-9274 (PAK4 and NAMPT inhibitor) Details Solid tumor/s | Phase 1 Update | |
XPOVIO (Selinexor) Details COVID-19 | Failed Discontinued | |
XPOVIO (Selinexor) (XPO1 inhibitor) Details Glioblastoma | Failed Discontinued | |
XPOVIO (Selinexor) (XPO1 inhibitor) Details Rare diseases, Liposarcoma, Cancer | Failed Discontinued | |
XPOVIO (Selinexor) (XPO1 inhibitor) + rituximab-gemcitabine-dexamethasone-platinum (R-GDP) Details Diffuse large B cell lymphoma | Failed Discontinued |